SCHEMBL631258

SCHEMBL631258

CC(C)Oc1ccc(C[C@H](NC(=O)C2CCCCN2S(=O)(=O)c2cccc(F)c2)C(=O)OCc2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNQ1 P51787 1/20 0.48
ITGB1 P05556 6/20 0.46
ITGA5 P08648 2/20 0.46
ITGA4 P13612 3/20 0.46
ITGB7 P26010 1/20 0.46
ELOVL6 Q9H5J4 1/20 0.46
LMNA P02545 1/20 0.43
FKBP1A P62942 6/20 0.43
ITGAV P06756 1/20 0.43
MMP2 P08253 2/20 0.42
MMP9 P14780 2/20 0.42
ITGA2 P17301 1/20 0.42
FKBP4 Q02790 1/20 0.42
FKBP5 Q13451 1/20 0.42
MMP1 P03956 2/20 0.41
MMP3 P08254 1/20 0.41
MMP7 P09237 1/20 0.41
MMP8 P22894 1/20 0.41
ADAM17 P78536 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL631259 1.00 KCNQ1 (0.48) KCNQ1ITGB1ITGA5ITGA4ITGB7
SCHEMBL630355 1.00 KCNQ1 (0.48) KCNQ1ITGB1ITGA5ITGA4ITGB7
SCHEMBL630937 0.91 ITGB1 (0.50) KCNQ1ITGB1ITGA5ITGA4ITGB7
SCHEMBL630272 0.91 ITGB1 (0.50) KCNQ1ITGB1ITGA5ITGA4ITGB7
SCHEMBL630255 0.91 ITGB1 (0.55) KCNQ1ITGB1ITGA5ITGA4ITGB7
SCHEMBL630271 0.91 ITGB1 (0.50) KCNQ1ITGB1ITGA5ITGA4ITGB7
SCHEMBL630250 0.91 ITGB1 (0.55) KCNQ1ITGB1ITGA5ITGA4ITGB7
SCHEMBL630254 0.91 ITGB1 (0.55) KCNQ1ITGB1ITGA5ITGA4ITGB7
SCHEMBL630249 0.91 ITGB1 (0.55) KCNQ1ITGB1ITGA5ITGA4ITGB7
SCHEMBL630273 0.91 ITGB1 (0.50) KCNQ1ITGB1ITGA5ITGA4ITGB7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778637-B1 FKBP-binding composition and pharmaceutical use thereof AVENTIS PHARMA INC (US) 2012-02-22 EP disclosed
US-7777042-B2 N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof AVENTIS PHARMACEUTICALS INC. (US) 2010-08-17 US disclosed
US-20080139556-A1 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2008-06-12 US disclosed
EP-1778637-A2 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF Aventis Pharmaceuticals, Inc. (US) 2007-05-02 EP disclosed
WO-2006012256-A2 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139556-A1 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF FKBP1A, FKBP1B, FKBP3 KCNQ1 4358/4885ITGB1 3840/4885ITGA5 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.